



## Biopharma Investor ESG Communications Guidance Update Released by Biopharma Sustainability Roundtable

*The updated Guidance reflects the progress of an ongoing dialog between biopharma companies and investors toward achieving more effective, efficient, and decision-useful ESG communications*

**Boston, San Francisco, Zurich, March 28, 2022** — The [Biopharma Sustainability Roundtable](#) (BSRT) has released the [Biopharma Investor ESG Communications Guidance 4.0](#), a resource for strategic thinking and planning of biopharma-investor ESG communications. The outcome of an ongoing dialog facilitated by the BSRT, the Guidance reflects a biopharma-investor consensus on the sector's priority ESG topics and offers recommendations on what and resources for how biopharma companies can most effectively communicate with investors about ESG strategy, governance, risks, opportunities, and performance. The Guidance 4.0 has been validated and improved through use-case experience by both biopharma and investors, and additional input from key stakeholders. Examples of best thinking on sector-specific metrics and key insights from the biopharma-investor dialog have also been included. The Guidance 4.0 offers a shared sector-specific point of reference for biopharma ESG practitioners, investors and their representatives, policymakers, and standard-setters.

Biopharma companies use the Guidance to anticipate the ESG information needs of capital market analysts, to enrich materiality reviews, to advance ESG strategic thinking within the executive team, and to trigger internal conversations across functions. Investors use it as an ESG primer for small and mid-size biopharma portfolio companies, as a guide to the biopharma sector ESG landscape that is integrated into their ESG analysis, and as a basis for stewardship engagements.

Development of the Guidance 4.0 has been a collaborative effort of the [Biopharma Investor ESG Communications Initiative](#) (the Initiative), with contributions from a core working group of biopharma companies (Sponsors: Bristol Meyers Squibb, Gilead, Johnson & Johnson, Merck & Co. (MSD), Novartis, Pfizer, Teva; and Contributors: Amgen, Novo Nordisk), together with an engaged community of investors and their representatives. An [Investor Statement of Support](#) accompanies the Guidance, underscoring its value and supporting the efforts of the Initiative's participants to improve biopharma-investor ESG communications within their companies. In the four years since the Initiative was launched, over 100 executives from more than 20 biopharma and 24 investor companies have engaged in this dialog. Conversations with key stakeholder groups, including major standard-setters, rating agencies and industry associations, also inform the updated Guidance.

Access the [Biopharma Investor ESG Communications Guidance 4.0](#) and the accompanying [Investor Statement of Support](#).

[Learn more](#) about the Biopharma Investor ESG Communications Initiative.



**Biopharma  
Sustainability  
Roundtable**

### **About the Biopharma Sustainability Roundtable**

The Biopharma Sustainability Roundtable is a sector-focused collaboration platform supporting senior biotech and pharma executives as they drive their Sustainability agendas forward. We facilitate a program of webinars and topical forums each Spring and an annual conference in the Fall, addressing a broad agenda of ESG topics defined in collaboration with our participants. Executives and invited thought leaders come together to explore Sustainability challenges and trends, examine cutting- edge industry topics, share best practices, and learn from each other. The Roundtable also facilitates topical initiatives that engage participating biopharma companies and key stakeholders, such as the Biopharma Investor ESG Communications Initiative.

Learn more at [biopharmasustainability.com](https://biopharmasustainability.com)

Contact us at [info@biopharmasustainability.com](mailto:info@biopharmasustainability.com)

# # #